Blueprint Medicines Corporation

Good morning, everyone. My name is Seb, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Blueprint Medicine's second quarter 2021 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, please press star followed by two. please plan to limit yourself to one question at a time. Thank you. I will now hand the floor to Kristin Hodes of Blueprint Medicines. Please go ahead.

Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicine's second quarter 2021 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at www.blueprintmedicines.com. Today on our call, Jeff Albers, our Chief Executive Officer, will discuss Blueprint Medicine's second quarter 2021 business highlights. Christy Rossi, our Chief Commercial Officer, will provide a commercial update. Becker Hughes, Chief Medical Officer, will review our recent clinical progress. and Mike Lansdell, our Chief Financial Officer, will review our second quarter 2021 financial results. Before we get started, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factor section of our SEC filings. In addition, any forward-looking statement made on this call represents our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. Now, here's our CEO, Jeff Albers.

Thanks, Kristen, and good morning, everyone. Thanks for joining us today to review our second quarter performance. The progress made across our portfolio in the second quarter puts us in the strongest position we've ever been in as a company. In January, we laid out our strategic priorities for 2021, which were one, to accelerate the global adoption of Avakit and Gavaretto. Two, to advance the next wave of therapeutic candidates into the clinic. And three, to further expand our precision therapy research pipeline. Underlying these three pillars is a single ambition. to build the world's leading precision medicine company and make real the promise of precision therapy to improve the lives of people with cancer and hematologic disorders. In June, we received US FDA approval of Avakit for the treatment of advanced systemic mastocytosis, or FM. This was a significant achievement for Blueprint and the culmination of nearly a decade of hard work from our team in partnership with the medical and patient communities. Systemic massive cytosis is a classic example of a rare disease, with a clear genetic driver that has been historically difficult to target. With AvaKit's approval, we're ushering in a new era of care for these patients with advanced SM, offering them the first targeted therapy designed to potently and selectively inhibit DA16B mutant kit, the central driver of their disease. As Christy will review shortly, we're seeing very encouraging early momentum across all aspects of the launch as we work to drive patient identification and access to treatment. It's particularly rewarding to see the momentum and efficiencies being realized as we deliver Avakit and Gavaretto to patients globally, both independently and through our partnerships. In parallel to the launch of Avakit and Advance-SM, we're making important progress across our clinical stage portfolio, as Becker will discuss later in the call. We now have six programs progressing through registration-enabling trials or into proof-of-concept studies. Our two product candidates for non-advanced SM, two product candidates for treatment-resistant EGFR-driven non-small-cell lung cancer, blue 222, our CDK2 inhibitor, and Blue 852, a MAP4K1 inhibitor developed under our cancer immunotherapy collaboration with Roche. What's exciting is that each of these programs could bring important innovation and improved outcomes for a large number of patients with significant medical need. Underpinning the promising scientific, clinical, and commercial execution is a very strong financial position, as Mike will discuss. Through our product launches and a purposeful mix of collaborations, we've enabled a diversified revenue stream that will further strengthen Blueprint and allow for meaningful across our business and portfolio as we continue our efforts to deliver transformative benefit to patients. So with that, I'll turn the call over to Christy to provide an update on our commercial efforts. Christy?